Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 212.96B +9.2% |
| Revenue (ttm) | 45.81B +2.7% |
| Net Income | 10.31B -6.6% |
| EPS | 5.34 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 20.96 |
| Forward PE | 14.58 |
| Dividend | 3.70 (2.82%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 2,804,355 |
| Open | 112.50 |
| Previous Close | 112.14 |
| Day's Range | 112.02 - 113.70 |
| 52-Week Range | 96.03 - 132.68 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 124.26 (+10.91%) |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 124.26, which is an increase of 10.91% from the latest price.
News
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Novartis: More Pain on the Way?
The bad diagnoses just keep on coming for the Swiss drugmaker.
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis investors to increase scrutiny of company’s strategy, Reuters reports
Novartis (NVS) investors will be increasing their scrutiny of the company’s dealmaking strategy following setbacks to drugs acquired through mergers and acquisitions, Bhanvi Satija, Oliver Hirt and Ma...
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its...
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Major Novartis shareholder calls for board shake-up after drug trial setbacks: Reuters exclusive
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker’s board to improve corporate governance after several trial setbacks.
Novartis shareholder calls for board changes, Reuters reports
A major Novartis (NVS) shareholder is calling for board changes following successive clinical setbacks and concerns over the company’s acquisition track record, arguing that stronger deal oversight an...
Stocks making the biggest moves premarket: Macy's, Meta, Apple, Novartis and more
These are the stocks posting the largest moves in the premarket.
Major Novartis shareholder calls for board shake-up after drug trial setbacks
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial...
HSBC upgrades Novartis to Hold with negative catalysts played out
HSBC last night upgraded Novartis (NVS) to Hold from Reduce with a price target of $136, up from $123. The firm believes the company’s negative catalyst path has played out…
Novartis upgraded to Hold from Reduce at HSBC
HSBC upgraded Novartis (NVS) to Hold from Reduce with a CHF 110 price target
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen d...
Anthropic has the right mindset when it comes to AI safety, says board Member Vas Narasimhan
Vas Narasimhan, CEO at Novartis and board member of Anthropic, joins 'Squawk on the Street' to respond to the recent statements of former researcher who warns that AI may soon prove to be a threat to ...
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss disappointing drug trial results soon after acquiring Avidity, the response to investors and more.
Novartis CEO on drug trial setbacks: We have the pipeline and replacement power to grow
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss disappointing drug trial results soon after acquiring Avidity, the response to investors, and more.
Novartis price target lowered to CHF 135 from CHF 142 at Citi
Citi lowered the firm’s price target on Novartis (NVS) to CHF 135 from CHF 142 and keeps a Buy rating on the shares.
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Dyne Therapeutics (DYN) to $36 from $45 and keeps an Overweight rating on the shares. The analyst says Novartis’ (NVS) Phase 3…
Novartis downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis last night downgraded Novartis (NVS) to Hold from Buy with a price target of CHF 120, down from CHF 140. The firm cites pelacarsen and…
Market Today: Novartis Plunges on Drug Trial Failures; US Market Drops
Market Today: Novartis Plunges on Drug Trial Failures; US Market Drops
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
European Markets Steady Amid Novartis Setbacks (NVS)
European Markets Steady Amid Novartis Setbacks (NVS)
Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tessa Romero downgraded Dyne Therapeutics (DYN) to Underweight from Neutral with a price target of $10, down from $17. The firm believes Novartis’ (NVS) Phase 3 trial miss…